ARTICLE | Finance
Building a British Shield
Why Switzerland's Shield Therapeutics is looking to list on the LSE
September 21, 2015 7:00 AM UTC
A London Stock Exchange IPO next month would complete Shield Therapeutics AG's transition from Switzerland to the U.K. by putting the biotech under a U.K. holding company.
CEO Carl Sterritt told BioCentury that when he co-founded Shield in 2008, the company opted to incorporate in Switzerland because "we thought the corporate tax situation was more beneficial for our shareholders than being a U.K.-based company." ...